Nephrotic syndrome

Published on 23/06/2015 by admin

Filed under Emergency Medicine

Last modified 23/06/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1334 times

16.6 Nephrotic syndrome

Introduction

Definition

Nephrotic syndrome (NS) refers to the findings of heavy proteinuria, hypoalbuminaemia, oedema and hyperlipidaemia, which result from a massive loss of protein in the urine secondary to glomerular disease. All components of the disease do not need to be present for diagnosis. The protein lost in the urine includes plasma proteins of molecular weight up to and including albumin. Generalised glomerular leak to macro-molecules does not occur in most cases, but can occur in severe disease. In severe disease, as there is progressive loss of glomerular permselectivity, renal clearance of IgG approaches that of albumin. Protein selectivity is seen mainly in minimal change nephrotic syndrome. The determination of protein selectivity has little clinical value but does increase the likelihood of response to steroid therapy.

The hallmarks of nephrotic syndrome are hypoalbuminaemia (serum albumin <30 g L–1), heavy proteinuria (>50 mg kg–1 body weight per 24 hours, or >1000 mg m–2 per 24 hours), generalised oedema and hyperlipidaemia (triglycerides and cholesterol).

Primary nephrotic syndrome (idiopathic) represents disease limited to the kidney. Disease is classified by responsiveness to steroid therapy (steroid sensitive, steroid dependent or steroid resistant) and histology on renal biopsy (minimal change, mesangial proliferative glomerulonephritis (GN) and focal segmental glomerulosclerosis, FSGS).

Secondary nephrotic syndrome represents multisystem disease that has kidney involvement, e.g. lupus nephritis, hereditary nephritis and Henoch–Schönlein purpura.

Certain drugs and chemicals can cause nephrotic syndrome, e.g. phenytoin, non-steroidal anti-inflammatory drugs, and captopril.

Pathophysiology

An immune basis for MCNS was proposed in 1974 but no primary immune abnormality has been identified. Studies have shown increased levels of circulating soluble interleukin-2 receptor in patients with active MCNS and FSGS. This soluble interleukin-2 receptor is shed by activated lymphocytes and may therefore indicate generalised activation of the immune system. However, this circulating soluble interleukin-2 receptor could serve as a neutraliser of circulating interleukin-2. It is unknown whether circulating levels represent evidence of activation or an attempt to down-regulate the immune responses.

There is hypercoagulability resulting from serum protein abnormalities introduced by renal protein wasting. All children with acute NS have increased platelet aggregation. Blood viscosity is increased and blood flow is reduced. Fibrinogen concentration is increased and antithrombin III is lost in the urine. All these factors contribute to this problem in NS.

The cause of cholesterolaemia and hypertriglyceridaemia remains uncertain. One theory is that reduced plasma oncotic pressure may stimulate lipoprotein synthesis and perhaps lipolytic factors may be lost in the urine.

Oedema reflects retention of salt and water. Reduced serum albumin causes a reduction in plasma oncotic pressure. When plasma oncotic pressure falls, intravascular volume is reduced, which stimulates proximal tubular reabsorption of sodium. The renin–angiotensin system is also stimulated, raising the serum aldosterone, which further increases distal tubular reabsorption of sodium. There is an increase in filtration capacity in patients with nephrotic syndrome along with an increase in glomerular permeability, resulting in proteinuria.

There is also evidence in some patients for primary salt and water retention by the kidney.